Intrust Bank’s Travere Therapeutics TVTX Stock Holding History

Intrust Bank’s Portfolio TVTX Stock Details TVTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-8,498	Closed	-$206K	–	389
2022 Q2	$206K	Buy	+8,498	New	+$214K	0.03%	372

Other funds holding TVTX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Intrust Bank's TVTX Position: Q3 2022 in Review

Intrust Bank sold out of Travere Therapeutics (TVTX) in Q3 2022, closing a stake of 8,498 shares — an estimated $206K sold.

Intrust Bank first reported a position in TVTX in Q2 2022 and held it in 1 quarter. The position peaked at $206K in Q2 2022. 171 funds tracked by Wall St. Rank hold TVTX as of Q3 2022.

Intrust Bank reported no remaining Travere Therapeutics position as of Q3 2022 after selling out during the quarter.
Intrust Bank sold 8,498 Travere Therapeutics shares in Q3 2022, an estimated $206K.
Intrust Bank first reported a position in Travere Therapeutics in Q2 2022 and held it in 1 quarter.
Intrust Bank's Travere Therapeutics position peaked at $206K in Q2 2022.
171 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2022.

Based on Intrust Bank's 13F filing for Q3 2022, filed 9 Nov 2022.